NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
Thank you for being part of our development since September 2001. With your ongoing support, we look forward to many exciting years ahead.
|
|
27 October 2026
| Name: | NEXSEN LIMITED (NXN) |
| ISIN: | AU0000418782 |
| Date of Listing: | 14 October 2025 |
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
This is a current registered entity, not in any form of external administration to our knowledge.Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
Automic Group
Level 5, 126 Philip Street Sydney NSW 2000
GPO Box 5193 Sydney NSW 2001
Tel : 1300 288 664 or +61 2 9698 5414
Fax : +61 2 8583 3040
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of Nexsen Limited will be lifted immediately following the release by NXN of an announcement regarding a proposed joint venture. | 25/09/2026 |
The proposed 50:50 FlashDx joint venture aims to develop an enhanced molecular Group B Streptococcus diagnostic test based on FlashDx's existing CE-marked product. This initiative accelerates market entry across Asia-Pacific, specifically Hong Kong and India, leveraging Nexsen's clinical network. Nexsen will fund and lead the regulatory pathway for US FDA and European CE-IVDR approvals, with the JV product targeting hospital and intrapartum testing, complementing rather than competing with Nexsen's StrepSure programme for antenatal screening. | 25/09/2026 |
Nexsen Limited's securities are suspended from quotation under Listing Rule 17.2 at NXN's request, pending an announcement, remaining suspended until either the specified period ends or the announcement is released. | 24/09/2026 |
listed entity carried for record purposes only | 14/10/2025 |
The suspension of trading in the securities of Nexsen Limited will be lifted immediately following the release by NXN of an announcement regarding a proposed joint venture. | 25/09/2026 |
The proposed 50:50 FlashDx joint venture aims to develop an enhanced molecular Group B Streptococcus diagnostic test based on FlashDx's existing CE-marked product. This initiative accelerates market entry across Asia-Pacific, specifically Hong Kong and India, leveraging Nexsen's clinical network. Nexsen will fund and lead the regulatory pathway for US FDA and European CE-IVDR approvals, with the JV product targeting hospital and intrapartum testing, complementing rather than competing with Nexsen's StrepSure programme for antenatal screening. | 25/09/2026 |
Nexsen Limited's securities are suspended from quotation under Listing Rule 17.2 at NXN's request, pending an announcement, remaining suspended until either the specified period ends or the announcement is released. | 24/09/2026 |
listed entity carried for record purposes only | 14/10/2025 |
Your browser may reflect a date of printing in American format.
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Reece O'Connell | Non Exec Chairman | |
| Mark Muzzin | Managing Director | |
| Richard Jarvis | CFO | 06/01/2026 |
| Martina Mariano | Non Exec Director | |
| Grant Pestell | Non Exec Director | |
| Shekhar Kumta | Executive Director | 03/12/2025 |
| Sonny Didugu | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|
Date of first appointment, title may have changed.
InvestoGain New Zealand | deListed New Zealand
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2026 Investogain Pty Limited. All rights reserved.
